Arvinas Inc (ARVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arvinas Inc (ARVN) has a cash flow conversion efficiency ratio of -0.086x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-48.30 Million) by net assets ($562.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Arvinas Inc for the company's overall valuation and market capitalisation.
Arvinas Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Arvinas Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arvinas Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arvinas Inc ranked by their cash flow conversion efficiency. Explore how high is Arvinas Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brainsway Ltd
NASDAQ:BWAY
|
0.015x |
|
Ramaco Resources Inc
NASDAQ:METC
|
-0.080x |
|
Quanta Storage
TWO:6188
|
0.205x |
|
eDreams Odigeo SA
MC:EDR
|
0.387x |
|
AirAsia X Bhd
KLSE:5238
|
-4.848x |
|
SGC Energy Co Ltd
KO:005090
|
-0.033x |
|
Queen's Road Capital Investment Ltd.
TO:QRC
|
0.002x |
|
M31 Technology Corp
TWO:6643
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Arvinas Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Arvinas Inc from 2016 to 2025. View today's stock price for Arvinas Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $433.80 Million | $-273.80 Million | -0.631x | -36.72% |
| 2024-12-31 | $561.70 Million | $-259.30 Million | -0.462x | +12.40% |
| 2023-12-31 | $660.00 Million | $-347.80 Million | -0.527x | -8.84% |
| 2022-12-31 | $564.90 Million | $-273.50 Million | -0.484x | -167.66% |
| 2021-12-31 | $781.70 Million | $559.40 Million | 0.716x | +612.02% |
| 2020-12-31 | $642.20 Million | $-89.76 Million | -0.140x | +22.01% |
| 2019-12-31 | $226.69 Million | $-40.63 Million | -0.179x | -51.97% |
| 2018-12-31 | $136.67 Million | $-16.12 Million | -0.118x | -100.57% |
| 2017-12-31 | $245.87K | $5.11 Million | 20.796x | +2675.61% |
| 2016-12-31 | $24.03 Million | $-19.40 Million | -0.807x | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more